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Background-—Observational studies suggest a survival advantage with bilateral single internal thoracic artery (BITA) versus single
internal thoracic artery grafting for coronary surgery, whereas this conclusion is not supported by randomized trials. We
hypothesized that this inconsistency is attributed to unmeasured confounders intrinsic to observational studies. To test our
hypothesis, we performed a meta-analysis of the observational literature comparing BITA and single internal thoracic artery,
deriving incident rate ratio for mortality at end of follow-up and at 1 year. We postulated that BITA would not affect 1-year survival
based on the natural history of coronary artery bypass occlusion, so that a difference between groups at 1 year could not be
attributed to the intervention.
Methods and Results-—We searched MEDLINE and Pubmed to identify all observational studies comparing the outcome of BITA
versus single internal thoracic artery. One-year and long-term mortality for BITA and single internal thoracic artery were
compared in the propensity-score–matched (PSM) series, that is, the form of observational evidence less prone to confounders.
Thirty-eight observational studies (174 205 total patients) were selected for final comparison. In the 12 propensity-score–
matched series (34 019 patients), the mortality reduction for BITA was similar at 1 year and at the end of follow-up (incident
rate ratio, 0.70; 95% confidence interval, 0.60–0.82 versus 0.77; 95% confidence interval, 0.70–0.85; P for subgroup
difference=0.43).
Conclusions-—Unmeasured confounders, rather than biological superiority, may explain the survival advantage of BITA in
observational series. ( J Am Heart Assoc. 2018;7:e008010. DOI: 10.1161/JAHA.117.008010.)
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A clear contradiction between observational and random-ized studies exists in the literature on the effect of
multiple internal thoracic artery grafts in patients undergoing
coronary artery bypass surgery.
In the 1980s, it was recognized that in coronary artery
bypass surgery patients long-term survival was enhanced
when the left anterior descending (LAD) was grafted with a
left internal thoracic artery, rather than a saphenous vein graft
(SVG).1 By extension, the use of bilateral internal thoracic
arteries (BITAs) should further increase postoperative survival,
compared with the use of a single internal thoracic artery
(SITA).2 This difference is generally attributed to greater and
more-durable patency of the internal thoracic artery com-
pared with the SVG, as well as increased late SVG
atherosclerosis.3
In the past 25 years, a very large amount of observational
data, including 6 meta-analyses,4–9 have supported this
concept. On this basis, the use of BITA is a class IIA
recommendation in patients with a long anticipated life
expectancy by current guidelines and professional society
position papers.10–12
The randomized studies, however, reported different
results. To date, there have been 4 randomized controlled
trials (RCTs) comparing BITA and SITA.13–16 In these studies,
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survival has been similar following BITA and SITA grafting. In
the largest of the RCTs, the ART (Arterial Revascularization
Trial), mortality was 8.7% after BITA grafting and 8.4%
following SITA at 5 years.16
There are several possible explanations for the discrepant
findings between observational and RCT evidence. The RCTs
may not have sufficient sample size or follow-up to detect a
mortality difference compared with observational series. In
the ART trial, a relatively higher proportion of crossovers in
the patients randomized to BITA, as well as the allowed use of
a radial artery in the SITA group, may have diluted the
treatment effect.
The other possible explanation, however, is that the benefit
observed in the observational studies for BITA grafting is
largely related to unmeasured confounders.
The objective of this study is to perform a meta-analysis of
the observational literature comparing survival following BITA
and SITA grafting. To evaluate whether unmeasured con-
founders rather than biological superiority explained the BITA
effect, we chose to compare both 1-year as well as late
survival in the BITA and SITA cohorts. We postulated that BITA
would not affect 1-year survival based on the natural history
of SVG occlusion. The latter analysis was restricted to
propensity-score–matched studies, because PSM is consid-
ered the best method to minimize confounding in observa-
tional series.
Methods
The data, analytical methods, and study materials will not be
made available to other researchers for purposes of repro-
ducing the results or replicating the procedure.
Search Strategy and Study Selection
This systematic review was conducted in accord to the
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses guidelines.17
Pubmed and OVID’s version of MEDLINE was searched
from January 1972 to August 2017 for publications comparing
BITA versus SITA grafting on all-cause mortality. The following
keywords were combined with the Boolean operator “or”:
“bilateral internal mammary,” “bilateral internal thoracic,”
“total arterial revascularization,” and “multiple arterial revas-
cularization.” The full search strategy can be found in Data S1.
All citations were screened for study inclusion independently
by 2 investigators (A.D.F. and M.G.). Any disagreements were
discussed and resolved by consensus. In addition, the
bibliography of all studies and meta-analyses was searched
to identify further publications.
Inclusion criteria for analysis were:
1. Observational study (unadjusted and adjusted studies
were eligible).
2. Sample size of at least 100 patients in each group.
3. Follow-up duration longer than 30 days.
4. Written in English language.
We excluded studies that were: RCTs, not performed in
humans, review articles, case reports, editorials, and expert
opinions. To ensure that the analysis was strictly limited to a
comparison of BITA versus SITA, we excluded studies where
an additional arterial graft was used in 1 of the 2 groups and it
was not possible to abstract the exact information for the
isolated BITA and SITA series. In case of overlapping between
studies or multiple publications from the same center, only
the publication with the largest sample size was considered.
The quality of included studies was assessed using the
Newcastle–Ottawa Scale for observational studies by 2
investigators independently (A.D.F. and M.G.).18 The highest
possible score is 9 stars; <6 stars was considered low quality
whereas ≥6 stars was considered high quality.
Data Abstraction
Two investigators (A.D.F. and M.G.) independently abstracted
the following: study demographics (study period, country, and
centers involved, sample size), study design methods, com-
pleteness of follow-up, and follow-up duration. In addition, the
following patient characteristics in the unmatched and
matched groups were also obtained: age, female sex, diabetes
mellitus, left ventricular ejection fraction, and chronic
obstructive pulmonary disease. Continuous variables were
expressed as median (25th, 75th percentile) or as meanSD.
Categorical variables are reported as frequency (%).
For all-cause mortality, crude event rates, unadjusted and
adjusted hazard ratios (HRs) for BITA versus SITA grafting, and
Clinical Perspective
What Is New?
• Our findings suggest that factors not related to the conduit
patency, such as the patients’ general status or quality of
the target vessels, play a role in determining the outcome of
observational studies and that a selection bias is present
even in propensity-score–matched analyses.
What Are the Clinical Implications?
• Our findings elicit concerns regarding the ability of the
propensity-matching process to overcome selection bias
and assure comparability between groups.
• The long-term clinical outcomes data from the ART (Arterial
Revascularization Trial) trial and new randomized studies are
needed to clarify the effect of bilateral internal thoracic
artery grafting in patients undergoing coronary bypass
surgery.
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their respective 95% confidence intervals (CIs) and log P-rank
values were abstracted.
Outcome Analyses
The primary outcome was all-cause mortality. Long-term all-
cause mortality for BITA and SITA patients was compared in
all the studies.
Subgroup analyses for the primary outcome were per-
formed as follows:
1. Studies in the general population versus studies in specific
subgroups of patients (ie, diabetics, elderly patients as
defined by the individual studies, patients with renal
failure, urgent/emergent cases, and patients with low
ejection fraction).
2. Unadjusted versus adjusted studies (including regression-
adjusted and PSM) in the general population.
3. Regression-adjusted versus PSM studies in the general
population.
To assess for possible treatment allocation bias in the
observational studies, we chose to compare 1-year mortality
between matched treatment groups. The 1-year interval was
chosen because the patency rate of SVGs at 1 year remains
high and a survival difference related to difference in patency
between arterial and venous conduits is unlikely.19 PSM is a
robust method used to balance against confounding by
indication in observational studies20; for this reason, we
compared all-cause mortality for BITA and SITA at 1 year in
the PSM studies only.
Analytical Plan
Long-term all-cause mortality between BITA and SITA patients
was compared in all studies initially. Comparisons were then
performed in the general population studies after exclusion of
studies restricted to specific patient subgroups (diabetes
mellitus, elderly as defined in the individual studies, renal
failure, urgent/emergent, and reduced left ventricular ejection
fraction) and in the individual specific patient subgroups.
Next, separate comparisons were made between BITA and
SITA in the unadjusted and adjusted series (covariate adjusted
and PSM combined). Last, comparisons were performed in the
covariate adjusted and PSM series separately.
One-year mortality between BITA and SITA patients was
compared in PSM studies only.
Statistical Analysis
The generic inverse variance method21 was used to pool the
natural logarithm of the incident rate ratio (IRR) across
studies to account for potentially different follow-up
durations between the groups. We estimated the IRR
through several means depending on the available study
data. When HRs were provided, we took the natural
logarithm of the HR; the SE was derived from the 95% CI
or log rank P value.22 When Kaplan–Meier curves were
present, we estimated the number of events from the curves
to calculate the IRR, as previously described.23 The SE was
estimated from the number of events in each arm.22 When
event rates were not readily available, they were extracted
from Kaplan–Meier curves using GetData Graph Digitizer
software (version 2.26; http://getdata-graph-digitizer.com/)
according to a previously described method.24
A random-effects model was used for statistical survival
pooling, computing risk estimates with 95% CIs. Funnel plots
were used to assess publication bias by graphical inspec-
tion.25 Hypothesis testing for equivalence was set at the
2-tailed 0.01 level. Hypothesis testing for statistical hetero-
geneity was set at the 2-tailed 0.10 level and was based on
the Cochran Q test, with I2 values of 0% to 25%, 26% to 50%,
and 51% to 100% representing low, moderate, and high
heterogeneity, respectively.26
Metaregression analysis examining the following variables
—age, sex, diabetes mellitus, and left ventricular ejection
fraction—was performed. In addition, a “leave-one-out”
analysis and a cumulative meta-analysis were performed in
all studies ordered by year of publication.
All analyses were performed using CMA software (version
3; Biostat, Englewood, NJ).
Results
Selected Studies
From 2921 titles, 149 pertinent studies were included for full-
text review. We excluded 111 studies that did not meet
inclusion criteria. Further details of the study flow are shown
in Figure S1. A total of 38 observational studies were selected
for the quantitative analysis. Eight nonadjusted, 9 covari-
ate-adjusted, and 21 PSM studies were included (see
Table 1).27–64 Twenty-eight studies (162 989 patients) were
performed in the general population, whereas 10 (11 216
patients) were performed in specific subgroups of patients
(diabetics: 3 studies [1533 patients]; elderly: 4 studies [6033
patients]; renal failure patients: 1 study [1203 patients];
urgent/emergent cases: 1 study [652 patients]; and patients
with low ejection fraction: 1 study [1795 patients]). An
overview of the studies is summarized in Tables 1 and 227–64
(variables included for PSM are summarized in Table S1).
The selected studies reported on 174 205 patients (BITA:
32 206; SITA: 141 999) for final comparisons.
Overall, the BITA and SITA groups presented different
preoperative risk-factor distribution (mean age, BITA versus
DOI: 10.1161/JAHA.117.008010 Journal of the American Heart Association 3
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Table 2. Overview of the Studies Included in the Primary Analysis
Study
Overall
Population, n UNM BITA, n UNM SITA, n PSM BITA, n PSM SITA, n Mean/Median Follow-up (Y)
Completeness
of Follow-up
Ashraf27 300 150 150 NA NA Median (IQR) BITA: 1.9 (1.3–2.6)
Median (IQR) SITA: 2.3 (1.7–3)
NR
Benedetto28 4195 750 3445 750 750 4.83.2 (PSM sample) 100%
Berreklouw29 482 NA NA 249 233 BITA: 9.72.7
SITA: 10.12.4
94%
Bonacchi30 652 NA NA 320 332 5.61.4 99.7%
Buxton31 2853 1296 1557 NA NA 4.3 95.9%
Calafiore32 1602 1026 576 570 570 Overall: 7.34.8
BITA: 7.15.0
SITA: 7.54.7
100%
Carrier33 6655 Statin+: 1166
Statin: 69
Statin+: 4835
Statin: 585
NA NA 10 99%
Dalen34 49 702 559 49 143 558 558 7.5 100%
Danzer35 521 382 139 NA NA 10 97.5%
Dewar36 1142 377 765 NA NA 4 NR
Endo37 1131 443 688 NA NA 6.2 99.3%
Gansera 200438 1378 716 662 NA NA 5.3 NR
Gansera 201739 250 NA NA 125 125 9.33.5 100%
Grau40 6666 1544 5122 1006 1006 Overall: 10.55
BITA: 10.95
SITA: 10.15
100%
Hirotani41 303 179 124 NA NA NR 95%
Itoh42 400 107 293 98 196 9.05.8 95.6%
Johnson43 2014 576 1438 NA NA NR 100%
Jones44 510 172 338 NA NA 5.03.1 100%
Joo45 1749 392 1357 366 366 Overall: 7.02.0
BITA: 6.92.1
SITA: 7.12.7
98.1%
Kelly46 7633 1079 6554 NA NA BITA: 5.4
SITA: 4.6
NR
Kieser47 5067 1038 4029 NA NA Overall: 7
BITA: 6.43.2
SITA: 7.13.4
NR
Kinoshita48 1203 750 453 412 412 PSM BITA: 5.63.3
PSM SITA: 4.93.2
99%
Kurlansky49 4584 2215 2369 Quintiles Quintiles Overall: 11.5
BITA: 12.7
SITA: 11.1
BITA=96.7%
SITA=98.3%
Locker50 8295 BITA only: 271
BITA/SVG: 589
7435 NR NR 7.64.6 100%
Lytle51 10 124 2001 8123 1152 1152 BITA: 16.22.4
SITA: 16.32.5
100%
Medalion52 1627 1045 582 NA NA 8.24.5 98%
Mohammadi53 1795 129 1666 111 111 Overall PSM: 8.05.3
PSM BITA: 8.65.1
PSM SITA: 7.75.5
92.7%
Continued
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SITA: 60 versus 64.1 years; female sex, BITA versus SITA: 16%
versus 20.8%; diabetes mellitus, BITA versus SITA: 32.2%
versus 40.5%; chronic obstructive pulmonary disease,
BITA versus SITA: 9.6% versus 11.8%; Table S2).
Long-Term All-Cause Mortality
Mean follow-up time across the 38 studies was 7.25 years
(range, 2.1–16.3). The overall mortality rate at the end of
follow-up was 28.0318.4% in the BITA versus 39.9623.5%
in the SITA series.
Use of BITA was associated with a statistically significant
reduction of mortality at the end of follow-up when compared
with SITA (IRR, 0.74; 95% CI, 0.69–0.80; P<0.001; I2=71%;
Figure 1A27–64 and Figure S2). This finding was consistent
across the general population and all the specific patient
subgroups and all the study designs (Figures S3 through S5)
and was not influenced by age, sex, diabetes mellitus, and
ejection fraction (Figure 2).
One-Year All-Cause Mortality in the PSM
Populations
Mean follow-up time of the 12 PSM studies was
7.414.4 years, and the number of patients included was
34 019. Use of BITA was associated with a similar reduction
of mortality at 1-year and at the end of follow-up (IRR, 0.70;
95% CI, 0.60–0.82 at 1 year versus IRR, 0.77; 95% CI, 0.70–
0.85 at the end of follow-up; P for subgroup differences=0.43;
Figure 3)* (details of the statistical analysis for the PSM
studies included in this analysis are summarized in Table S3).
These findings were robust in a leave-one-out analysis
(Figure 4).†
Publication Bias and Internal Validity Appraisal
Study quality was high across all studies included in the
primary analysis (Table S4). Overall heterogeneity was high
both at 1-year analysis in the PSM studies (I2=51%) and at end
of follow-up in the overall studies analysis (I2=71%). Publica-
tion bias was low, as assessed by funnel plots, for all-cause
mortality in the primary analysis (Figure 5).
An overview of the results of all the analyses is provided in
Table S5.
Discussion
For almost 25 years, the concept that the use of BITA is
associated with improved survival after coronary artery
bypass surgery has been accepted in the cardiovascular
community. This concept is almost completely based on
observational studies.
To date, at least 60 English-language observational studies
comparing the clinical outcome of BITA and SITA patients
Table 2. Continued
Study
Overall
Population, n UNM BITA, n UNM SITA, n PSM BITA, n PSM SITA, n Mean/Median Follow-up (Y)
Completeness
of Follow-up
Nasso54 8054 4088 3966 3584 3584 3.1 98%
Naunheim55 365 100 265 100 100 NR 96.5%
Navia56 2486 2098 388 485 NR Median: 5.5 (IQR: 2.6–8.8) 95%
Parsa57 17 609 728 16 881 NA NA NR 100%
Pettinari58 3496 1328 2168 892 892 3.1 100%
Pick59 321 NA NA 160 161 9.82.8 100%
Rosenblum60 8254 873 7381 306 306 Median: 2.8 (IQR: 1.1–4.9) 100%
Schwann61 5125 641 4484 551 551 NR 100%
Stevens62 4382 1835 2547 NA NA Overall: 113
BITA: 82
SITA: 123
98%
Tarelli63 300 150 150 NA NA Overall: 9.2
BITA: 9.22.8
SITA: 9.12.5
100%
Toumpoulis64 980 NA NA 490 490 4.73.0 99.1%
BITA indicates bilateral internal thoracic arteries; IQR, interquartile range; NA, not applicable; NR, not reported; PSM, propensity-score matched; SITA, single internal thoracic artery; SVG,
saphenous vein graft.
*References 28, 32, 34, 40, 45, 46, 49, 51, 54, 60–62.
†References 28, 32, 34, 40, 45, 46, 49, 51, 54, 60–62.
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have been published (Figure S1). The overwhelming majority
of these have shown better outcomes in the BITA treatment
group. Several reports have also suggested that the advan-
tages of BITA grafting could be extended to females,65
diabetics,66 and patients with chronic renal insufficiency.48
Over time, this evidence has been summarized in 6 meta-
analyses.4–9 All of them showed a significant and similar
survival advantage, as measured by the HR, for the use of
BITA (see Table 3).4–9
Our analysis pools data from 38 of these studies and
174 205 patients and confirms the previous findings
(Table 3).4–9 We used IRRs instead of HR or relative risk
ratio to account for potential differences in follow-up duration
within studies and between studies. We confirmed better
long-term survival for BITA compared with SITA (IRR, 0.74;
95% CI, 0.69–0.80; P<0.001; Figure 1A).27–64 This difference
was evident independently from the patient population
included and the methodology used (Figures S3 through
S5). The benefit was uncertain from 1989 to 2000, was
consistently significant at the 0.05 level starting in 2001, and
crossed the 0.01 and 0.001 levels in 2004 (Figure 1B).27–64
Basing on these data, the current US10 and European11
Guidelines encourage the use of a second arterial graft in
patients with a long life expectancy, and last year the Society
of Thoracic Surgeons published a position paper strongly
encouraging a wider use of arterial grafts.12
Figure 1. A, Forest plot comparing the effect of the use of BITA vs SITA on end of follow-up mortality across all the included studies (38
studies; 174 205 patients). B, Cumulative analysis of all the included studies using random-effect model (38 studies; 174 205 patients). BITA
indicates bilateral internal thoracic artery; CI, confidence interval; SITA, single internal thoracic artery. Incident rate ratio (IRR) is used.
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It must, however, be noted that the results of the
observational studies have not been confirmed in the random-
ized comparisons. The 4 RCTs that have compared BITA and
SITA to date have all failed to show a survival difference
between the 2 revascularization strategies.13–16 Two of the
RCTs were small, with less than 100 patients in each arm, and
had limited follow-up, so that they were probably underpow-
ered to detect moderate differences.13,14 Another study was
moderate in size (Stand-in-Y,15 800 patients) and the most
recent, the ART trial,16 included more than 3000 patients.
The Stand-in-Y Mammary study compared the outcomes of
800 patients randomized to receive BITA using 2 different
configurations: SITA and radial artery or SITA and saphenous
vein.15 At a mean follow-up of 24.19.8 months, no differ-
ence in survival was found between the BITA and SITA groups
(P=0.62; odds ratio, 0.63; 95% CI, 0.27–1.47), although
Figure 1. Continued
DOI: 10.1161/JAHA.117.008010 Journal of the American Heart Association 9
BITA for CABG Gaudino et al
S
Y
S
T
E
M
A
T
IC
R
E
V
IE
W
A
N
D
M
E
T
A
-A
N
A
L
Y
S
IS
patients with arterial grafts had better cardiac event–free
survival (Wilcoxon test, P<0.0001).
The ART trial randomized 3102 patients to receive 1 or 2
internal thoracic arteries.16 The primary end point is overall
survival, and the study was designed to be able to detect a 20%
reduction in the primary end point at 10 years. At a planned 5-
year interim analysis, no difference in survival (91.3% in the
BITA group and 91.6% in the SITA group; HR, 1.04; CI, 0.81–
1.32) or in the composite of mortality, myocardial infarction,
and/or stroke (12.2% BITA versus 12.7% SITA; HR, 0.96; CI,
0.79–1.17) was found between groups.
Several methodological flaws in the design of the RCTs can
partially explain the variance between the results of the
randomized and observational studies. All the RCTs were
limited to mid-term follow-up, and it is known the attrition rate
of saphenous grafts remains low at 5 years19; it is possible
that a difference between the groups would have become
apparent with further follow-up. There are additional consid-
erations specifically regarding the ART study that may explain
a negative result. A sizeable proportion (23%) of patients
randomized to SITA also received a radial artery as an
additional arterial graft. There was a high rate of crossover in
the group allocated to BITA (16.4%). There was very high
compliance with optimal medical therapy in both groups (90%
of patients on aspirin, beta-blockers, and statins). Finally,
there was a treatment age interaction that approached
statistical significance, favoring BITA in patients aged <70
years whereas BITA appeared harmful in patients aged >70.
There are, however, biological reasons in support of the
results of the RCTs. A second arterial conduit to a non-LAD
Figure 2. Results of the metaregression analyses. Univariate metaregression analysis showed that the effect of BITA was not influenced by
age (slope P value=0.625; intercept P value=0.941), sex (slope P value=0.160; intercept P value=0.0002), diabetes mellitus (slope P
value=0.730; intercept P value=0.0001), and ejection fraction (slope P value=0.674; intercept P value=0.482). Similarly, multivariate
metaregression analysis showed that the effect of BITA was not influenced by age (slope P value=0.270), sex (slope P value=0.412), diabetes
mellitus (slope P value=0.848), and ejection fraction (slope P value=0.644) with intercept P value=0.487 (plot not shown). BITA indicates
bilateral internal thoracic artery; DM, diabetes mellitus; EF, ejection fraction.
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target has less potential to impact on overall survival than the
single left internal thoracic artery to the LAD. Solid evidence
suggests, in fact, that in coronary artery bypass surgery, patient
survival is mainly determined by the status of the LAD and that
grafts to non-LAD vessels are more likely to affect other cardiac
end points (myocardial infarction, angina recurrence, and need
Figure 3. Forest plot comparing the effect of the use of BITA vs SITA on end of follow-up (top) and 1-year (bottom) mortality in PSM studies in
the general population (12 studies; 34 019 patients). BITA indicates bilateral internal thoracic artery; CI, confidence interval; PSM, propensity-
score matched; SITA, single internal thoracic artery. Incident rate ratio (IRR) is used.
Figure 4. Leave-one-out analyisis for 1-year mortality among PSM studies (12 studies). BITA indicates
bilateral internal thoracic artery; CI, confidence interval; PSM, propensity-score matched; SITA, single
internal thoracic artery. Incident rate ratio (IRR) is used.
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for revascularization), but not overall survival.27–29 The LAD
also can provide collaterals to other coronaries (commonly the
right coronary); a persistently patent internal thoracic artery
graft to the LAD can therefore supply not only the anterior wall,
but, through collaterals, viable myocardium in other territories.
Last, patency of grafts to the LAD generally exceed the patency
of grafts to non-LAD vessels.3
Our hypothesis, however, is that the difference in results
between the RCTs and the observational evidence is
attributed to unmeasured confounders and not to the
difference in revascularization strategy.
In order to test this hypothesis, we repeated the BITA
versus SITA comparison at 1 year, when the attrition rate of
the SVGs is still low and a survival difference attributable to a
difference in graft patency is unlikely.
Because PSM studies are considered the observational
studies less prone to confounders, we decided to limit the 1-
year analysis to PSM studies only.
Figure 5. Publication bias as assessed by funnel plots for all-cause mortality in the primary analysis. A, All included studies. B, Studies
performed in the general population vs studies performed in specific subpopulations. C, Unadjusted studies vs adjusted studies. D, PSM studies
vs adjusted non-PSM studies. E, PSM studies at 1-year follow-up vs PSM studies at end of follow-up. PSM indicates propensity-score matched.
Table 3. Published Meta-Analyses of the Observational Evidence on the BITA vs SITA Comparison
First Author, Year
Studies Included in
Survival Analysis, n
Patients Included in
Survival Analysis, n
Type of Observational
Studies Included
Patient Populations Excluded
by Inclusion Criteria HR in Favor of BITA
Taggart, 20015 7 15 962 All None 0.81 [95% CI 0.70–0.94]
Rizzoli, 20024 7 15 299 All High-risk patients,
emergencies, diabetics
0.79 [95% CI 0.66–0.91]
Weiss, 20137 27 79 063 All None 0.78 [95% CI 0.72–0.84]
Takagi, 20146 20 70 897 Adjusted None 0.80 [95% CI 0.77–0.84]
Yi, 20148 9 15 583 Adjusted None 0.79 [95% CI 0.75–0.84]
Buttar, 20179 29 89 399 All None 0.78 [95% CI 0.72–0.84]
BITA indicates bilateral internal thoracic artery; HR, hazard ratio; PSM, propensity-score matched; UNM, unmatched.
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In fact, PSM series constitute a large amount of the current
evidence in the surgical fields.20 The PSM process is thought
to be able to minimize differences in the preoperative risk
profile of the patients, and PSM studies are often quoted as
the best level of evidence after RCTs.20
We found that the relative survival advantage attributed to
the BITA group at 1 year was similar to that observed at late
follow-up (Figure 3).‡
This finding suggests that factors not related to the conduit
patency, such as the patients’ general status or quality of the
target vessels, played a role in determining the outcome and
that unmatched biases are present even in PSM studies.
The use of the BITA increases the complexity and
invasiveness of the procedure. It is likely that surgeons tend
to reserve this operation for the patients perceived as
healthier and with longer life expectancy from a cardiac and a
general health perspective. A bias may also exist in terms of
the graftability and location of the target vessels. This type of
“eye-balling” or clinical acumen based on the individual
surgeon’s experience is very difficult to quantify; the statistics
can only be adjusted for the measured, and not for the
unmeasured, confounders. Our findings elicit concerns on the
ability of the propensity-matching process to overcome
treatment allocation biases in observational studies and
assure comparability between groups.
Limitations
This analysis shares the common limitations of meta-analysis
of observational data, although the funnel plots do not
indicate important publication bias.
In addition, the different studies included different surgical
techniques (on- versus off-pump) and grafting strategies
(single versus composite grafts) as well as different definitions
and matching algorithms, so that the homogeneity of the
included population cannot be regarded as optimal.
In most of the series, the 1-year IRR was not specified in
the original study and had to be derived using the described
statistical methods.
Upon careful review of the methods of the PSM studies, we
could not confer that the original studies adjusted the
variance estimates appropriately for the matched nature of
the data in the original studies (Table S3). That said, the HRs
would still be correct, and the leave-one-out analysis was
consistent with the overall findings.
Finally, given that we included only articles in English, a
language bias cannot be excluded, although there are no
plausible biological reasons to support it.
Conclusions
In conclusion, the present meta-analysis challenges the
benefit traditionally attributed to BITA grafting. The fact that,
even in the PSM series, BITA patients exhibit a significant
survival advantage at 1-year follow-up suggests that unmea-
sured confounders may account for the reported survival
benefit of BITA in the observational series.
In addition, our results suggest that even our best
statistical methods to minimize baseline demographic differ-
ences in observational studies have major limitations.
Later reporting of the clinical outcomes of ART and new
randomized studies are needed to clarify the effect of BITA
grafting in patients undergoing CABG.
Sources of Funding
Prof Fremes is partially supported by the Bernard S. Goldman
Chair in Cardiovascular Surgery.
Disclosures
Prof Fremes is supported, in part, by the Bernard S. Goldman
Chair in Cardiovascular Surgery. The remaining authors have
no disclosures to report.
References
1. Loop FD, Lytle BW, Cosgrove DM, Stewart RW, Goormastic M, Williams GW,
Golding LA, Gill CC, Taylor PC, Sheldon WC. Influence of the internal-
mammary-artery graft on 10-year survival and other cardiac events. N Engl J
Med. 1986;314:1–6.
2. Lytle BW, Blackstone EH, Loop FD, Houghtaling PL, Arnold JH, Akhrass R,
McCarthy PM, Cosgrove DM. Two internal thoracic artery grafts are better
than one. J Thorac Cardiovasc Surg. 1999;117:855–872.
3. Tatoulis J, Buxton BF, Fuller JA. Patencies of 2127 arterial to coronary conduits
over 15 years. Ann Thorac Surg. 2004;77:93–101.
4. Rizzoli G, Schiavon L, Bellini P. Does the use of bilateral internal mammary
artery (IMA) grafts provide incremental benefit relative to the use of a single
IMA graft? A meta-analysis approach. Eur J Cardiothorac Surg. 2002;22:781–
786.
5. Taggart DP, D’Amico R, Altman DG. Effect of arterial revascularisation on
survival: a systematic review of studies comparing bilateral and single internal
mammary arteries. Lancet. 2001;358:870–875.
6. Takagi H, Goto S, Watanabe T, Mizuno Y, Kawai N, Umemoto T. A meta-
analysis of adjusted hazard ratios from 20 observational studies of bilateral
versus single internal thoracic artery coronary artery bypass grafting. J Thorac
Cardiovasc Surg. 2014;148:1282–1290.
7. Weiss AJ, Zhao S, Tian DH, Taggart DP, Yan TD. A meta-analysis
comparing bilateral internal mammary artery with left internal mammary
artery for coronary artery bypass grafting. Ann Cardiothorac Surg.
2013;2:390–400.
8. Yi G, Shine B, Rehman SM, Altman DG, Taggart DP. Effect of bilateral internal
mammary artery grafts on long-term survival: a meta-analysis approach.
Circulation. 2014;130:539–545.
9. Buttar SN, Yan TD, Taggart DP, Tian DH. Long-term and short-term outcomes
of using bilateral internal mammary artery grafting versus left internal
mammary artery grafting: a meta-analysis. Heart. 2017;103:1419–1426.
10. Hillis LD, Smith PK, Anderson JL, Bittl JA, Bridges CR, Byrne JG, Cigarroa JE,
Disesa VJ, Hiratzka LF, Hutter AM, Jessen ME, Keeley EC, Lahey SJ, Lange RA,
London MJ, Mack MJ, Patel MR, Puskas JD, Sabik JF, Selnes O, Shahian DM,
Trost JC, Winniford MD. 2011 ACCF/AHA guideline for coronary artery bypass
graft surgery: a report of the American College of Cardiology Foundation/‡References 28, 32, 34, 40, 45, 46, 49, 51, 54, 60–62.
DOI: 10.1161/JAHA.117.008010 Journal of the American Heart Association 13
BITA for CABG Gaudino et al
S
Y
S
T
E
M
A
T
IC
R
E
V
IE
W
A
N
D
M
E
T
A
-A
N
A
L
Y
S
IS
American Heart Association Task Force on Practice Guidelines. Circulation.
2011;124:e652–e735.
11. Authors/Task Force members, Windecker S, Kolh P, Alfonso F, Collet JP,
Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, J€uni P, Kappetein AP, Kastrati
A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P,
Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W,
Witkowski A. 2014 ESC/EACTS guidelines on myocardial revascularization:
the Task Force on Myocardial Revascularization of the European Society of
Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery
(EACTS). Developed with the special contribution of the European Association
of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J.
2014;35:2541–2619.
12. Aldea GS, Bakaeen FG, Pal J, Fremes S, Head SJ, Sabik J, Rosengart T,
Kappetein AP, Thourani VH, Firestone S, Mitchell JD; Society of Thoracic
Surgeons. The Society of Thoracic Surgeons clinical practice guidelines on
arterial conduits for coronary artery bypass grafting. Ann Thorac Surg.
2016;101:801–809.
13. Myers WO, Berg R, Ray JF, Douglas-Jones JW, Maki HS, Ulmer RH, Chaitman
BR, Reinhart RA. All-artery multigraft coronary artery bypass grafting with only
internal thoracic arteries possible and safe: a randomized trial. Surgery.
2000;128:650–659.
14. Gaudino M, Cellini C, Pragliola C, Trani C, Burzotta F, Schiavoni G, Nasso G,
Possati G. Arterial versus venous bypass grafts in patients with in-stent
restenosis. Circulation. 2005;112:I265–I269.
15. Nasso G, Coppola R, Bonifazi R, Piancone F, Bozzetti G, Speziale G. Arterial
revascularization in primary coronary artery bypass grafting: direct comparison
of 4 strategies—results of the Stand-in-Y Mammary Study. J Thorac Cardiovasc
Surg. 2009;137:1093–1100.
16. Taggart DP, Altman DG, Gray AM, Lees B, Gerry S, Benedetto U, Flather M.
Randomized trial of bilateral versus single internal-thoracic-artery grafts. N
Engl J Med. 2016;375:2540–2549.
17. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting
items for systematic reviews and meta-analyses: the PRISMA statement. PLoS
Med. 2009;6:e1000097.
18. Wells G, Shea B, O’Connel D, Peterson J, Welch V, Losos M, Tugwell P. The
Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised
studies in meta-analyses. [Internet]. 2011. Available at: http://www.ohri.ca/
programs/clinical_epidemiology/oxford.asp. Accessed September 15, 2017.
19. Benedetto U, Raja SG, Albanese A, Amrani M, Biondi-Zoccai G, Frati G.
Searching for the second best graft for coronary artery bypass surgery: a
network meta-analysis of randomized controlled trials†. Eur J Cardiothorac
Surg. 2015;47:59–65; discussion, 65.
20. Lonjon G, Boutron I, Trinquart L, Ahmad N, Aim F, Nizard R, Ravaud P.
Comparison of treatment effect estimates from prospective nonrandomized
studies with propensity score analysis and randomized controlled trials of
surgical procedures. Ann Surg. 2014;259:18–25.
21. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials.
1986;7:177–188.
22. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-
analyses of the published literature for survival endpoints. Stat Med.
1998;17:2815–2834.
23. Yanagawa B, Verma S, J€uni P, Tam DY, Mazine A, Puskas JD, Friedrich JO. A
systematic review and meta-analysis of in situ versus composite bilateral
internal thoracic artery grafting. J Thorac Cardiovasc Surg. 2017;153:1108–
1116.e16.
24. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for
incorporating summary time-to-event data into meta-analysis. Trials.
2007;8:16.
25. Rothstein HR, Sutton AJ, Borenstein M. Publication Bias in Meta-Analysis:
Prevention, Assessment and Adjustments. Chichester, UK: John Wiley & Sons
Ltd; 2005.
26. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in
meta-analyses. BMJ. 2003;327:557–560.
27. Ashraf SS, Shaukat N, Akhtar K, Love H, Shaw J, Rowlands DJ, Keenan D. A
comparison of early mortality and morbidity after single and bilateral internal
mammary artery grafting with the free right internal mammary artery. Br Heart
J. 1994;72:321–326.
28. Benedetto U, Amrani M, Gaer J, Bahrami T, de Robertis F, Simon AR, Raja SG;
Harefield Cardiac Outcomes Research Group. The influence of bilateral internal
mammary arteries on short- and long-term outcomes: a propensity score
matching in accordance with current recommendations. J Thorac Cardiovasc
Surg. 2014;148:2699–2705.
29. Berreklouw E, Rademakers PP, Koster JM, van Leur L, van der Wielen
BJ, Westers P. Better ischemic event-free survival after two internal
thoracic artery grafts: 13 years of follow-up. Ann Thorac Surg. 2001;72:
1535–1541.
30. Bonacchi M, Maiani M, Prifti E, Di Eusanio G, Di Eusanio M, Leacche M.
Urgent/emergent surgical revascularization in unstable angina: influence of
different type of conduits. J Cardiovasc Surg (Torino). 2006;47:201–210.
31. Buxton BF, Komeda M, Fuller JA, Gordon I. Bilateral internal thoracic artery
grafting may improve outcome of coronary artery surgery. Risk-adjusted
survival. Circulation. 1998;98:II1–II6.
32. Calafiore AM, Di Giammarco G, Teodori G, Di Mauro M, Iaco AL, Bivona A,
Contini M, Vitolla G. Late results of first myocardial revascularization in
multiple vessel disease: single versus bilateral internal mammary artery with
or without saphenous vein grafts. Eur J Cardiothorac Surg. 2004;26:542–
548.
33. Carrier M, Cossette M, Pellerin M, Hebert Y, Bouchard D, Cartier R, Demers P,
Jeanmart H, Page P, Perrault LP. Statin treatment equalizes long-term survival
between patients with single and bilateral internal thoracic artery grafts. Ann
Thorac Surg. 2009;88:789–795; discussion, 795.
34. Dalen M, Ivert T, Holzmann MJ, Sartipy U. Bilateral versus single internal
mammary coronary artery bypass grafting in Sweden from 1997-2008. PLoS
One. 2014;9:e86929.
35. Danzer D, Christenson JT, Kalangos A, Khatchatourian G, Bednarkiewicz M,
Faidutti B. Impact of double internal thoracic artery grafts on long-term
outcomes in coronary artery bypass grafting. Tex Heart Inst J. 2001;28:89–
95.
36. Dewar LR, Jamieson WR, Janusz MT, Adeli-Sardo M, Germann E, MacNab JS,
Tyers GF. Unilateral versus bilateral internal mammary revascularization.
Survival and event-free performance. Circulation. 1995;92:II8–II13.
37. Endo M, Nishida H, Tomizawa Y, Kasanuki H. Benefit of bilateral over single
internal mammary artery grafts for multiple coronary artery bypass grafting.
Circulation. 2001;104:2164–2170.
38. Gansera B, Loef A, Angelis I, Gillrath G, Schmidtler F, Kemkes BM. Double
thoracic artery—halved mid-term mortality? A 5-year follow-up of 716 patients
receiving bilateral ITA versus 662 patients with single ITA. Z Kardiol.
2004;93:878–883.
39. Gansera B, Delalic A, Eszlari E, Eichinger W. 14-year results of bilateral versus
single internal thoracic artery grafts for left-sided myocardial revascularization
in young diabetic patients. Thorac Cardiovasc Surg. 2017;65:272–277.
40. Grau JB, Johnson CK, Kuschner CE, Ferrari G, Shaw RE, Brizzio ME, Zapolanski
A. Impact of pump status and conduit choice in coronary artery bypass: a 15-
year follow-up study in 1412 propensity-matched patients. J Thorac Cardiovasc
Surg. 2015;149:1027–1033.e2.
41. Hirotani T, Nakamichi T, Munakata M, Takeuchi S. Risks and benefits of
bilateral internal thoracic artery grafting in diabetic patients. Ann Thorac Surg.
2003;76:2017–2022.
42. Itoh S, Kimura N, Adachi H, Yamaguchi A. Is bilateral internal mammary arterial
grafting beneficial for patients aged 75 years or older? Circ J. 2016;80:1756–
1763.
43. Johnson WD, Brenowitz JB, Kayser KL. Factors influencing long-term (10-year
to 15-year) survival after a successful coronary artery bypass operation. Ann
Thorac Surg. 1989;48:19–24; discussion, 24–25.
44. Jones JW, Schmidt SE, Miller CC, Beall AC, Baldwin JC. Bilateral internal
thoracic artery operations in the elderly. J Cardiovasc Surg (Torino).
2000;41:165–170.
45. Joo HC, Youn YN, Yi G, Chang BC, Yoo KJ. Off-pump bilateral internal thoracic
artery grafting in right internal thoracic artery to right coronary system. Ann
Thorac Surg. 2012;94:717–724.
46. Kelly R, Buth KJ, Legare JF. Bilateral internal thoracic artery grafting is superior
to other forms of multiple arterial grafting in providing survival benefit after
coronary bypass surgery. J Thorac Cardiovasc Surg. 2012;144:1408–1415.
47. Kieser TM, Lewin AM, Graham MM, Martin B-J, Galbraith PD, Rabi DM, Norris
CM, Faris PD, Knudtson ML, Ghali WA; APPROACH Investigators. Outcomes
associated with bilateral internal thoracic artery grafting: the importance of
age. Ann Thorac Surg. 2011;92:1269–1275; discussion, 1275–1276.
48. Kinoshita T, Asai T, Suzuki T. Off-pump bilateral skeletonized internal thoracic
artery grafting in patients with chronic kidney disease. J Thorac Cardiovasc
Surg. 2015;150:315–321.e3.
49. Kurlansky PA, Traad EA, Dorman MJ, Galbut DL, Zucker M, Ebra G. Thirty-year
follow-up defines survival benefit for second internal mammary artery in
propensity-matched groups. Ann Thorac Surg. 2010;90:101–108.
50. Locker C, Schaff HV, Dearani JA, Joyce LD, Park SJ, Burkhart HM, Suri RM,
Greason KL, Stulak JM, Li Z, Daly RC. Multiple arterial grafts improve late
survival of patients undergoing coronary artery bypass graft surgery: analysis
of 8622 patients with multivessel disease. Circulation. 2012;126:1023–1030.
51. Lytle BW, Blackstone EH, Sabik JF, Houghtaling P, Loop FD, Cosgrove DM. The
effect of bilateral internal thoracic artery grafting on survival during 20
postoperative years. Ann Thorac Surg. 2004;78:2005–2012; discussion,
2012–2014.
DOI: 10.1161/JAHA.117.008010 Journal of the American Heart Association 14
BITA for CABG Gaudino et al
S
Y
S
T
E
M
A
T
IC
R
E
V
IE
W
A
N
D
M
E
T
A
-A
N
A
L
Y
S
IS
52. Medalion B, Mohr R, Ben-Gal Y, Nesher N, Kramer A, Eliyahu S, Pevni D.
Arterial coronary artery bypass grafting is safe and effective in elderly patients.
J Thorac Cardiovasc Surg. 2015;150:607–612.
53. Mohammadi S, Kalavrouziotis D, Cresce G, Dagenais F, Dumont E, Charbon-
neau E, Voisine P. Bilateral internal thoracic artery use in patients with low
ejection fraction: is there any additional long-term benefit? Eur J Cardiothorac
Surg. 2014;46:425–431; discussion, 431.
54. Nasso G, Popoff G, Lamarra M, Romano V, Coppola R, Bartolomucci F, Giglio
MD, Romeo F, Tavazzi L, Speziale G. Impact of arterial revascularization in
patients undergoing coronary bypass. J Card Surg. 2012;27:427–433.
55. Naunheim KS, Barner HB, Fiore AC. 1990: results of internal thoracic artery
grafting over 15 years: single versus double grafts. 1992 update. Ann Thorac
Surg. 1992;53:716–718.
56. Navia DO, Vrancic M, Piccinini F, Camporrotondo M, Dorsa A, Espinoza J,
Benzadon M, Camou J. Myocardial revascularization exclusively with bilateral
internal thoracic arteries in T-graft configuration: effects on late survival. Ann
Thorac Surg. 2016;101:1775–1781.
57. Parsa CJ, Shaw LK, Rankin JS, Daneshmand MA, Gaca JG, Milano CA, Glower
DD, Smith PK. Twenty-five-year outcomes after multiple internal thoracic
artery bypass. J Thorac Cardiovasc Surg. 2013;145:970–975.
58. Pettinari M, Sergeant P, Meuris B. Bilateral internal thoracic artery grafting
increases long-term survival in elderly patients. Eur J Cardiothorac Surg.
2015;47:703–709.
59. Pick AW, Orszulak TA, Anderson BJ, Schaff HV. Single versus bilateral internal
mammary artery grafts: 10-year outcome analysis. Ann Thorac Surg.
1997;64:599–605.
60. Rosenblum JM, Harskamp RE, Hoedemaker N, Walker P, Liberman HA, de
Winter RJ, Vassiliades TA, Puskas JD, Halkos ME. Hybrid coronary
revascularization versus coronary artery bypass surgery with bilateral or
single internal mammary artery grafts. J Thorac Cardiovasc Surg.
2016;151:1081–1089.
61. Schwann TA, Hashim SW, Badour S, Obeid M, Engoren M, Tranbaugh RF,
Bonnell MR, Habib RH. Equipoise between radial artery and right internal
thoracic artery as the second arterial conduit in left internal thoracic artery-
based coronary artery bypass graft surgery: a multi-institutional study. Eur J
Cardiothorac Surg. 2016;49:188–195.
62. Stevens LM, Carrier M, Perrault LP, Hebert Y, Cartier R, Bouchard D, Fortier A,
El-Hamamsy I, Pellerin M. Single versus bilateral internal thoracic artery grafts
with concomitant saphenous vein grafts for multivessel coronary artery bypass
grafting: effects on mortality and event-free survival. J Thorac Cardiovasc Surg.
2004;127:1408–1415.
63. Tarelli G, Mantovani V, Maugeri R, Chelazzi P, Vanoli D, Grossi C, Ornaghi D,
Panisi P, Sala A. Comparison between single and double internal mammary
artery grafts: results over ten years. Ital Heart J. 2001;2:423–427.
64. Toumpoulis IK, Anagnostopoulos CE, Balaram S, Swistel DG, Ashton RC,
DeRose JJ. Does bilateral internal thoracic artery grafting increase long-term
survival of diabetic patients? Ann Thorac Surg. 2006;81:599–606; discussion,
606–607.
65. Gansera B, Gillrath G, Lieber M, Angelis I, Schmidtler F, Kemkes BM. Are men
treated better than women? Outcome of male versus female patients after
CABG using bilateral internal thoracic arteries. Thorac Cardiovasc Surg.
2004;52:261–267.
66. Raza S, Sabik JF, Masabni K, Ainkaran P, Lytle BW, Blackstone EH. Surgical
revascularization techniques that minimize surgical risk and maximize late
survival after coronary artery bypass grafting in patients with diabetes
mellitus. J Thorac Cardiovasc Surg. 2014;148:1257–1264; discussion, 1264–
1266.
S
Y
S
T
E
M
A
T
IC
R
E
V
IE
W
A
N
D
M
E
T
A
-A
N
A
L
Y
S
IS
DOI: 10.1161/JAHA.117.008010 Journal of the American Heart Association 15
BITA for CABG Gaudino et al
 
 
 
 
 
 
 
 
SUPPLEMENTAL MATERIAL 
 
Data S1 
Database: Ovid MEDLINE: Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid 
MEDLINE® Daily and Ovid MEDLINE® <1946-Present> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     bilateral internal mammary.mp. (331) 
2     bilateral internal thoracic.mp. (434) 
3     1 or 2 (756) 
4     exp Internal Mammary-Coronary Artery Anastomosis/ (2248) 
5     3 or 4 (2765) 
6     limit 5 to english language (2396) 
7     limit 6 to case reports (576) 
8     6 not 7 (1820) 
9     limit 8 to "review" (127) 
10     8 not 9 (1693) 
11     total arterial revascularization.mp. (153) 
12     multiple arterial revascularization.mp. (8) 
13     11 or 12 (160) 
14     (arterial revascularization adj6 coronary).mp. [mp=title, abstract, original title, name of 
substance word, subject heading word, keyword heading word, protocol supplementary concept 
word, rare disease supplementary concept word, unique identifier, synonyms] (95) 
15     13 or 14 (224) 
16     (multiple arterial adj6 coronary).mp. [mp=title, abstract, original title, name of substance 
word, subject heading word, keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier, synonyms] (39) 
17     (total arterial adj6 coronary).mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier, synonyms] (87) 
18     15 or 16 or 17 (311) 
19     limit 18 to (english language and humans) (247) 
20     limit 19 to (case reports or comment or editorial or "review") (71) 
21     19 not 20 (176) 
22     10 or 21 (1822) 
 
***************************
Table S1. Pre-treatment variables included for propensity score-matching. 
Study Variables  
Benedetto1 Age, sex, NYHA class, MI, PCI, smoking, COPD, CVA, PVD, AF, LMD, number of vessels diseased, LVEF <50%, BMI ≥30, creatinine ≥200 mmol/L, 
DM, preoperative IABP, urgent/emergent, resident performing procedure, CPB 
Calafiore2 COPD, no. of anastomoses, DM, extra-cardiac vasculopathy, EF ≤35%, sex, urgency, age, CHF, CRF, previous MI, unstable angina, ventricular 
arrhythmias 
Dalen3 NR 
Gansera 20164 Age, sex, number of grafts, EF, elective, urgent/emergent operations, preoperative MI, preoperative PCI or preoperative stent 
Grau5 Sex, age, BMI, DM, history of smoking and current smoking status, hypertension, CVA, no. of diseased coronary vessels, PVD, NYHA class IV, 
stroke, COPD, previous MI, renal failure, LMD, LVEF, creatinine, cardiogenic shock presentation, prior cardiac surgery, urgency status 
Itoh6  Sex, DM, use of insulin, obesity, hypertension, dyslipidemia, PAD, CRF, CVA, previous MI, LVEF <40%, involvement of the left main coronary 
trunk, triple-vessel disease, double-vessel disease, urgent/emergency surgery 
Joo7 Age, sex, DM, peripheral occlusive disease, prior PCI, CRF, recent MI, 3-vessel disease, LVEF, low LVEF (<35%) 
Kelly8 Age, sex, BMI, smoking history, DM, renal failure, hypertension, PVD, cardiovascular disease, COPD, LVEF <40%, CHF, recent MI (less than 7 
days), prior PCI, urgency of surgery, left main/triple vessel disease, surgeon 
Kinoshita9 Age, age group, sex, BMI, BSA, DM, HbA1C, oral hypoglycemic agents, insulin, GFR, dialysis, hypertension, COPD, PAD, CVA, LVEF <40%, previous 
PCI, MI, CHF, NYHA class III or IV, LV diastolic dimensions, LV systolic dimensions, LVEF, no. of target coronary arteries 
Kurlansky10 NR 
Locker11 Age, sex, BSA, LVEF, hypertension, DM, chronic lung disease, renal failure, PVD, previous MI, CVA 
Lytle12 Sex, age, BMI, previous MI, severe LV dysfunction, HF symptoms, no. of vessels with ≥50% stenosis, % stenosis in the left main trunk, stenosis 
≥50% in the LAD system, stenosis ≥50% in the Cx system, stenosis ≥50% in the RCA system, NYHA class, family history of CAD, hypertension, DM, 
history of smoking, COPD, PVD, cholesterol, surgeon, date of operation  
Medalion13 Age, sex, DM, hyperlipidemia, PVD, emergency surgery, critical preoperative state, recent MI, acute MI, repeat operation, renal insufficiency, 
CHF, COPD, unstable angina, LMD, no. of diseased vessels, LVEF 
Mohammadi14 Age, sex, hypertension, COPD, DM, insulin-dependent DM, PVD or cerebral vascular disease (or both), previous stroke, BMI ≥30 kg/m2, renal 
failure, creatinine value, previous MI, LMD, NYHA, surgical acuity, Parsonnet score, smoking status, previous PCI 
Nasso15 NR 
Navia16 Age, sex, DM, hypertension, dyslipidemia, smoking habit, family history, elective operation, on-pump operation, LV dysfunction 
(moderate/severe), LMD, three-vessel disease, redo operation, previous MI, previous PCI, PVD, carotid artery disease, abdominal aortic 
aneurysm, COPD, cerebrovascular disease, previous renal dysfunction 
Pettinari17 OPCAB, surgeon, age, preoperative creatinine, sex, length, weight, BMI, preoperative dialysis, carotid stenosis, simultaneous carotid surgery, 
presence of carotid occlusion, history of stroke, PVD, shock or CPR, acute MI, urgency, recent myocardial infarction, perioperative AF, DM, COPD, 
FEV1, coronary vessel diseased, degree LM stenosis, redo, mild aortic stenosis, mild mitral insufficiency, EF, BBB, LV hypertrophy, experience, 
end diastolic pressure 
Rosenblum18 Age, sex, race, height, weight, BMI, current smoker, DM, cerebrovascular disease, chronic lung disease, dyslipidemia, hypertension, PVD, renal 
failure, GFR, hemoglobin, previous MI, HF, LVEF, isolated LMD, left main plus other vessel, three-vessel disease, aspirin use, beta blocker use, STS 
predicted risk for mortality, STS risk morbidity/mortality, year of procedure 
Schwann19 Age, EF, vessel disease, no. of grafts, completeness of revascularization index, sex, obesity, DM, insulin-dependent DM, DM and obesity, DM or 
obesity, hypertension, hypercholesterolemia, COPD, smoker, previous MI, PVD, previous surgery, LMD, no. of diseased vessels, no. of grafts, 
deep sternal infection, bleeding post-operation 
Stevens20 Age, sex, DM, hypertension, unstable angina, prior MI, preoperative PCI, perioperative need for IABP, CHF, PVD, obesity, dyslipidemia, COPD, no. 
of coronary artery bypass grafts 
Toumpoulis21 EuroSCORE, age, sex, race, vessels involved, unstable angina, previous MI, transmural MI, more than one previous MI, previous cardiac 
operation, CCS angina class, urgency of the operation, hemodynamic instability, shock, EF categories, current CHF, past CHF, PVD, BMI 
categories, hypertension, COPD, calcified aorta, renal failure, preoperative dialysis, hepatic failure, immune deficiency, preoperative IABP, IV 
NTG, LV hypertrophy, malignant ventricular arrhythmia, thrombolysis prior surgery, previous PCI, smoking previous year 
AF, preoperative atrial fibrillation; BITA, bilateral thoracic arteries; BMI, body mass index; BSA, body surface area; CBP, cardio-pulmonary bypass; CCS, Canadian Cardiovascular Society; CHF, 
congestive heart failure; COPD, chronic obstructive pulmonary disease; CPR, cardio-pulmonary resuscitation; Cr, creatinine; CRF, chronic renal failure; CVA, previous cerebrovascular accident; Cx, 
circumflex coronary artery; DIA, diagonal coronary artery; DM, diabetes mellitus; EF, ejection fraction; FEV1, Forced expiratory volume in the 1st second; IABP, intra-aortic balloon pump; ITA, 
internal thoracic artery; IVNTG, intravenous nitroglycerine; LAD, left anterior descending; LMD, left main disease; LV, left ventricle; MI, myocardial infarction; NYHA, New York Heart Association; 
NR, not reported; OPCAB, off-pump coronary artery bypass grafting; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; PVD, peripheral vascular disease; RCA, right coronary 
artery; STS, Society of Thoracic Surgeons. 
  
Table S2. Risk factor distribution in the populations of the studies included in the primary analysis. 
Study Age (y) Mean±SD Female (%) DM (%) EF COPD (%) 
Ashraf22      
BITA 57 (median) 23 10 55% (median) NR 
SITA 59 (median) 21 10.7 58% (median) NR 
Benedetto1      
BITA NR (Ranges) 10.8 15.9 EF<50% in 13.2% 7.7 
SITA NR (Ranges) 21.2 31.5 EF<50% in 22.1% 10.6 
Berreklouw23      
BITA 53.7 10.4 6 NR NR  
SITA 56 16.3 7.4 NR NR  
Bonacchi24      
BITA 59 ± 14 18 30 EF<35% in 19% 14 
SITA 63 ± 11 20 34 EF<35% in 21% 16 
Buxton25      
BITA 58.6 ± 9 10.6 6.8 EF<50% in 4.9% NR 
SITA 64.9 ± 9 22 19.9 EF<50% in 24.2% NR 
Calafiore2      
BITA 60.7 ± 8.3 19.3 24.2 59.4 ± 13.1 2.8 
SITA 60.8 ± 9.0 17.5 24.2 59.3 ± 13.8 3 
Carrier26      
BITA 61 ± 9 16 21 NR NR 
SITA 68 ± 8 29 31 NR NR 
Dalen3      
BITA 64.4 ± 11.1 25.9 13.7 EF<30% in 4.3% 4.3 
SITA 66.7 ± 9.2 21 22.8 EF<30% in 3.2% 4.6 
Danzer27      
BITA 59.8 ± 8.8 12 13.6 EF<40% in 13.6 NR 
SITA 57.1 ± 8.5 10.1 13 EF<40% in 13 NR 
Dewar28      
BITA NR 15.4 17.7 NR NR 
SITA NR 16.6 19.3 NR NR 
Endo29      
BITA 61 (median) 9.7 42.9 54% (median) NR 
SITA 62 (median) 19.2 40.3 54% (median) NR 
Gansera 200430      
BITA 69.2 (median) 16 26 NR NR 
SITA 71 (median) 23 25.9 NR NR 
Gansera 20164      
BITA 59.3 ± 5.3 17 100 NR NR 
SITA 60.1 ± 5.3 17 100 NR NR 
Grau5      
BITA 60 ± 9 10.4 11 51 ± 11 5.1 
SITA 62 ± 9 12.1 13.3 50 ± 12 5.9 
Hirotani31      
BITA 64.8 ± 7.8 23 100 48.2 ± 15.1 NR 
SITA 63.9 ± 8.9 25 100 48.8 ± 16.4 NR 
Itoh6      
BITA 77.6 ± 2.5 23.4 37.4 EF<40% in 10.3% NR 
SITA 78.2 ± 2.8 36.2 37.3 EF<40% in 7.2% NR 
Johnson32      
BITA NR NR NR NR NR 
SITA NR NR NR NR NR 
Jones33      
BITA 69.2 19.2 NR EF<50% in 38.9% NR 
SITA 69.7 9.8 NR EF<50% in 39.6% NR 
Joo7      
BITA 60.4 ± 9.1 39.8 38.3 57 ± 11% 7.4 
SITA 61.3 ± 7.5 37.2 40.8 55 ± 11% 6.7 
Kelly8      
BITA 58.4 ± 10.0 18 26 EF<40% in 7% 11 
SITA 65.0 ± 10.1 25 37 EF<40% in 12% 14 
Kieser34      
BITA 58 ± 9.1 NR 27.8 EF<20% in 0.4% NR 
SITA 67.6 ± 9.5 NR 26.2 EF<20% in 0.4% NR 
Kinoshita9      
BITA 69 ± 8 16 61 52 ± 14% 19 
SITA 71 ± 9 24 55 53 ± 14% 22 
Kurlansky10      
BITA 62.9 ± 10.0 14.9 20.8 EF<30% in 3.9% NR 
SITA 67.5 ± 9.4 25.7 27.3 EF<30% in 6.2% NR 
Locker11      
BITA NR NR NR NR NR 
SITA 68 ± 9 24.8 33.5 NR 11.7 
Lytle12      
BITA 57.5 ± 8.1 12 12 NR NR 
SITA  57.8 ± 8.3 14 12 NR NR 
Medalion13      
BITA NR (ranges) 27 32.2 EF≤30% in 8.2% 5.5 
SITA NR (ranges) 33.7 38.3 EF≤30% in 7.7% 12.9 
Mohammadi14      
BITA 54.6 ± 9.5 9.3 14 EF≤30% in 30.2% 12.4 
SITA 65.2 ± 9.6 19 42.9 EF≤30% in 34.5% 19.2 
Nasso15      
BITA 67.3 ± 9.3 20.4 42.8 EF<30% in 10.2% 9.9 
SITA 66.9 ± 9.1 21.4 48.4 EF<30% in 10.1% 10.1 
Naunheim35      
BITA 49.6 ± 7.9 17 4 NR NR 
SITA 51.3 ± 6.6 13 3 NR NR 
Navia16      
BITA 63.7 ± 9.1 9.8 25.9 NR 4.2 
SITA NR NR NR NR NR 
Parsa36      
BITA 59 (median) 19.8 14.7 51% (median) 3.9 
SITA 64 (median) 28.5 29.9 52% (median) 8.2 
Pettinari17      
BITA 73.2 ± 2.8 26.1 12.6 44.3 ± 32.2 16.3 
SITA 74.5 ± 3.5 32.9 16.2 45.0 ± 30.9 21.4 
Pick37      
BITA 60 18 17.5 58% NR 
SITA 62 20 27 57% NR 
Rosenblum18      
BITA 59.0 ± 10.1 15.5 27.6 52.2 ± 11.0 1.8 
SITA 63.8 ± 10.6 28.7 43.8 51.7 ± 12.4 6.3 
Schwann19      
BITA 59.8 ± 10.2 12 15 54 ± 11 6.4 
SITA 65.3 ± 10.4 35 37 49 ± 12 22 
Stevens20      
BITA 57 ± 9 12 12 NR 4 
SITA 63 ± 9 25 18 NR 6 
Tarelli38      
BITA 56.5 ± 8.2 7.3 11.3 57.2 ± 13.6 NR 
SITA 59.3 ± 8.3 17.3 24.7 54.5 ± 13.5 NR 
Toumpoulis21      
BITA 63.6 ± 9.9 44.9 100 EF<30% in 20.6% 15.5 
SITA 64.5 ± 9.4 43.9 100 EF<30% in 19.2% 17.3 
COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; EF, ejection fraction; NR, not reported; SD, standard deviation. 
  
Table S3. Details of statistical analysis for the propensity score matched studies included in the 1-year analysis. 
Study Year  PSM methods Cox regression adjusted for matched sample Statistical Software 
Benedetto1 2014 Greedy 1:1 matching Yes R 
Calafiore2 2004 Stepwise logistic 
regression (nearest 
neighbor matching) 
No SPSS 
Dalen3 2014 Logistic regression and 
nearest neighbor 
matching without 
replacement 
Yes STATA 
Grau5 2015 Nearest-neighbor 
matching algorithm 
with greedy 5-1 digit 
matching 
No NS 
Joo7 2012 Logistic regression 
model, 1:1 ratio 
No SPSS 
Kelly8 2012 NR No SAS 
Kurlansky10 2010 Rosenbaum optimal 
matching algorithm 
using Mahalanobis 
distance within 
No NCSS 
propensity score 
calipers  
Lytle12 2004 NR NS NS 
Nasso15 2012 1:1 matching with 
maximum allowable 
difference: 
0.1 
No NS 
Rosenblum18 2016 Logistic regression No SPSS 
Schwann19 2016 Logistic regression Yes SPSS 
Stevens20 2004 NR Yes SAS 
NR, not reported; NS, not specified. 
  
Table S4. Newcastle-Ottawa Scale for the studies included in the primary analysis. 
Study Selection  Comparability Outcome/Exposure 
Ashraf22 **** ** ** 
Benedetto1 **** ** *** 
Berreklouw23 **** ** *** 
Bonacchi24 **** ** *** 
Buxton25 **** ** *** 
Calafiore2 **** ** *** 
Carrier26 **** ** *** 
Dalen3 **** ** *** 
Danzer27 ****  ** 
Dewar28 **** ** * 
Endo29 **** ** *** 
Gansera 200430 ****  ** 
Gansera 20164 **** ** ** 
Grau5 **** ** *** 
Hirotani31 **** * ** 
Itoh6 **** ** *** 
Johnson32 ****  *** 
Jones33 **** * *** 
Joo7   **** ** *** 
Kelly8 **** ** ** 
Kieser34 **** ** ** 
Kinoshita9 **** ** *** 
Kurlansky10 **** ** *** 
Locker11 **** ** *** 
Lytle12  **** ** *** 
Medalion13 **** ** *** 
Mohammadi14 **** ** *** 
Nasso15 **** ** *** 
Naunheim35 **** ** *** 
Navia16 **** ** *** 
Parsa36 **** ** *** 
Pettinari17 **** ** *** 
Pick37 **** ** *** 
Rosenblum18 **** ** *** 
Schwann19 **** ** ** 
Stevens20 **** ** *** 
Tarelli38 ****  *** 
Toumpoulis21 **** ** *** 
 
  
Table S5. Overview of the results 
Outcomes summary Studies Effect Estimate  
IRR [95%CI] 
Heterogeneity Overall effect Favors 
All studies  
 
38 0.74(0.69-0.80) I2=71%, p< 
0.00001 
Z=8.26, p< 0.00001 BITA 
All studies, excluding those performed in 
specific subpopulations  
 
28 0.74(0.68-0.80) I2=77%, p< 
0.00001 
Z=6.94, p< 0.00001 BITA 
Studies performed in specific 
subpopulations  
 
10 0.73(0.63-0.86) I2=24%, p= 0.22 Z=4.88, p< 0.00001 BITA 
Unadjusted studies 6 0.68(0.58-0.80) I2=56%, p= 0.04 Z=3.52, p= 0.0004 BITA 
Adjusted studies 22 0.79(0.74-0.85) I2=54%, p= 0.001 Z=5.59, p< 0.00001 BITA 
Adjusted non-PSM studies  
 
10 0.84(0.76-0.93) I2=38%, p= 0.09 Z=3.09, p= 0.002 BITA 
PSM studies (end of follow-up) 
 
12 0.77(0.70-0.85) I2=37%, p= 0.09 Z=6.82, p< 0.00001 BITA 
PSM studies (1-year follow-up)  12 0.70(0.60-0.82) I2=51%, p= 0.02 Z=3.14, p= 0.002 BITA 
BITA, bilateral internal thoracic artery; CI, confidence interval; IRR, incidence rate ratio; PSM, propensity score matching 
 
Figure S1. Flow chart for study selection. 
 
 
  
Figure S2. Leave-one-out analysis for the end of follow-up mortality among all the studies included in the primary analyisis (38 studies). Incident 
rate ratio (IRR) is used. 
 
 
  
Figure S3. Forest plots comparing the effect of the use of BITA vs SITA on end of follow-up mortality after the exclusion of studies performed in 
specific subpopulations (28 studies; 162,989 patients, top) and in those studies performed in specific subpopulations (10 studies; 11,216 patients, 
bottom). (BITA, bilateral internal thoracic artery; CI, confidence interval; SITA, single internal thoracic artery). Incident rate ratio (IRR) is used. 
 
 
 
  
Figure S4. Forest plots comparing the effect of the use of BITA vs SITA on end of follow-up mortality in adjusted (22 studies; 155, 925 patients, 
top) and unadjusted (6 studies; 7064 patients, bottom) studies in the general population. (BITA, bilateral internal thoracic artery; CI, confidence 
interval; SITA, single internal thoracic artery). Incident rate ratio (IRR) is used. 
 
 
  
Figure S5. Forest plots comparing the effect of the use of BITA vs SITA on end of follow-up mortality in adjusted-non PSM studies (10 studies; 
43,855 patients, top) and PSM studies (12 studies; 34,019 patients, bottom) in the general population. (BITA, bilateral internal thoracic artery; CI, 
confidence interval; PSM, propensity score matched; SITA, single internal thoracic artery). Incident rate ratio (IRR) is used. 
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